170 related articles for article (PubMed ID: 25293773)
1. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma.
Kolstad A; Kumari S; Walczak M; Madsbu U; Hagtvedt T; Bogsrud TV; Kvalheim G; Holte H; Aurlien E; Delabie J; Tierens A; Olweus J
Blood; 2015 Jan; 125(1):82-9. PubMed ID: 25293773
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Grant BW; Jung SH; Johnson JL; Kostakoglu L; Hsi E; Byrd JC; Jones J; Leonard JP; Martin SE; Cheson BD
Cancer; 2013 Nov; 119(21):3797-804. PubMed ID: 23922187
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
Cartron G; Zhao-Yang L; Baudard M; Kanouni T; Rouillé V; Quittet P; Klein B; Rossi JF
J Clin Oncol; 2008 Jun; 26(16):2725-31. PubMed ID: 18427151
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
8. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
Flowers CR
Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
[TBL] [Abstract][Full Text] [Related]
9. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
11. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
12. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K
BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561
[TBL] [Abstract][Full Text] [Related]
13. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
14. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
[No Abstract] [Full Text] [Related]
18. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
[TBL] [Abstract][Full Text] [Related]
19. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
Bendandi M; Gocke CD; Kobrin CB; Benko FA; Sternas LA; Pennington R; Watson TM; Reynolds CW; Gause BL; Duffey PL; Jaffe ES; Creekmore SP; Longo DL; Kwak LW
Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
[TBL] [Abstract][Full Text] [Related]
20. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
